AIMS: Inflammation is a key regulatory process that links hypercholesterolemia and immune mechanisms promoting atherosclerosis. Inflammatory biomarkers may be helpful to better define the atherosclerotic burden in patients with high cholesterol levels such as familial hypercholesterolemia (FH). Our aim was to evaluate the concentration of S100A12 protein in FH patients and its association with pulse wave velocity (PWV). METHODS: We measured glucose and lipid profile, S100A12, sRAGE, esRAGE and PWV in 39 patients with a genetically confirmed diagnosis of FH and 39 hypercholesterolemic subjects without a clinical diagnosis of FH (Dutch score ≤ 3). All subjects were on statin treatment at the time of the enrollment. RESULTS: No difference of glucose and lipid profile was found in the two groups. FH patients had higher S100A12 plasma levels than non-FH subjects (12.87 ± 4.82 vs. 8.57 ± 4.87 ng/mL, p < 0.01). No difference of hs-CRP, sRAGE and esRAGE was found between the two groups. Also, PWV was higher in FH patients than non-FH subjects (8.63 ± 0.92 vs. 6.68 ± 0.73 m/s, p < 0.05). Finally, S100A12 was independently correlated with age (p < 0.01), genetic mutation (p < 0.01) and PWV (p < 0.001). CONCLUSIONS: FH patients exhibited higher S100A12 levels than non-FH subjects. A novel vascular inflammation pathway, other than hs-CRP, might be useful to better characterize cardiovascular risk profile.
AIMS: Inflammation is a key regulatory process that links hypercholesterolemia and immune mechanisms promoting atherosclerosis. Inflammatory biomarkers may be helpful to better define the atherosclerotic burden in patients with high cholesterol levels such as familial hypercholesterolemia (FH). Our aim was to evaluate the concentration of S100A12 protein in FHpatients and its association with pulse wave velocity (PWV). METHODS: We measured glucose and lipid profile, S100A12, sRAGE, esRAGE and PWV in 39 patients with a genetically confirmed diagnosis of FH and 39 hypercholesterolemic subjects without a clinical diagnosis of FH (Dutch score ≤ 3). All subjects were on statin treatment at the time of the enrollment. RESULTS: No difference of glucose and lipid profile was found in the two groups. FHpatients had higher S100A12 plasma levels than non-FH subjects (12.87 ± 4.82 vs. 8.57 ± 4.87 ng/mL, p < 0.01). No difference of hs-CRP, sRAGE and esRAGE was found between the two groups. Also, PWV was higher in FHpatients than non-FH subjects (8.63 ± 0.92 vs. 6.68 ± 0.73 m/s, p < 0.05). Finally, S100A12 was independently correlated with age (p < 0.01), genetic mutation (p < 0.01) and PWV (p < 0.001). CONCLUSIONS:FHpatients exhibited higher S100A12 levels than non-FH subjects. A novel vascular inflammation pathway, other than hs-CRP, might be useful to better characterize cardiovascular risk profile.
Authors: Arianna Toscano; Maria Cinquegrani; Michele Scuruchi; Antonino Di Pino; Salvatore Piro; Viviana Ferrara; Carmela Morace; Alberto Lo Gullo; Egidio Imbalzano; Francesco Purrello; Giovanni Squadrito; Roberto Scicali; Giuseppe Mandraffino Journal: Biomolecules Date: 2022-04-09
Authors: Amilia Aminuddin; Md Rizman M L M Lazim; Adila A Hamid; Chua K Hui; Mohd H Mohd Yunus; Jaya Kumar; Azizah Ugusman Journal: Mediators Inflamm Date: 2020-08-18 Impact factor: 4.711
Authors: Stefania Di Mauro; Alessandra Scamporrino; Agnese Filippello; Maurizio Di Marco; Maria Teresa Di Martino; Francesca Scionti; Antonino Di Pino; Roberto Scicali; Roberta Malaguarnera; Francesco Purrello; Salvatore Piro Journal: Int J Mol Sci Date: 2022-07-25 Impact factor: 6.208
Authors: Roberto Scicali; Giorgio Ivan Russo; Marina Di Mauro; Flavia Manuele; Grazia Di Marco; Antonino Di Pino; Viviana Ferrara; Agata Maria Rabuazzo; Salvatore Piro; Giuseppe Morgia; Francesco Purrello Journal: J Clin Med Date: 2020-11-08 Impact factor: 4.241